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AbstrAct
Background Reduced left ventricular ejection fraction 
(LVEF) is a risk marker for mortality after an acute coronary 
syndrome (ACS). Global Registry of Acute Coronary Events 
(GRACE) risk score, developed almost two decades ago, is 
the preferred scoring system for risk stratification in ACS. 
The aim of this study was to validate the GRACE score and 
evaluate whether LVEF has incremental predictive value 
over the GRACE in predicting 6-month mortality after ACS 
in a contemporary setting.
Methods A retrospective analysis of all 1576 consecutive 
patients who were admitted to Tays Heart Hospital and 
underwent coronary angiography for a first episode of 
ACS (2015–2016). Clinical risk factors were extensively 
recorded. Adjusted Cox regression analysis was used to 
analyse the associations between LVEF and the GRACE 
score with 6-month all-cause mortality. The incremental 
predictive value was assessed by the change in C-statistic 
by Delong’s method for paired samples and by index of 
discrimination improvement (IDI).
Results In univariable analysis, both LVEF and the 
GRACE were associated with 6-month mortality, and 
after applying both variables into the same model, the 
results remained significant (GRACE score: HR: 1.036, 
95% CI 1.030 to 1.042; LVEF: HR: 0.965, 95% CI 0.948 
to 0.982, both HRs corresponding to a one unit change in 
the exposure variable). The GRACE score demonstrated 
good discrimination for mortality (C-statistic: 0.833, 95% 
CI 0.795 to 0.871). Adding LVEF to the model with the 
GRACE score improved model performance significantly 
(C-statistic: 0.848, 95% CI 0.813 to 0.883, p=0.029 for the 
improvement and IDI 0.0171, 95% CI 0.0016 to 0.0327, 
p=0.031).
Conclusions Adding LVEF to the GRACE score 
significantly improves risk prediction of 6-month mortality 
after ACS.
IntRoduCtIon
Acute coronary syndrome (ACS) repre-
sents one of the leading causes of death 
in the western countries.1 ACS refers to a 
spectrum of clinical conditions ranging 
from ST-segment elevation myocardial 
infarction (STEMI) to non-ST-segment eleva-
tion myocardial infarction (NSTEMI) and 
unstable angina.2 Numerous risk assessment 
instruments have been developed to quan-
tify the risk of mortality among patients with 
ACS.3 4 Currently, the Global Registry of 
Acute Coronary Events (GRACE) clinical risk 
score is the most frequently used and recom-
mended.4–7
According to previous studies, reduced 
left ventricular ejection fraction (LVEF) is 
associated with an increased risk of death in 
ACS.8–10 LVEF was not included in the devel-
opment of the GRACE score and very little 
is known about possible improvement of 
prognostic evaluation in patients with ACS 
by adding LVEF to the GRACE score. Based 
on one retrospective registry of patients 
treated between 2004 and 2005, LVEF seems 
to have uncertain or little additional value 
Key questions
What is already known about this subject?
 ► The Global Registry of Acute Coronary Events 
(GRACE) score performs well in prediction of 
6-month all-cause mortality in acute coronary syn-
drome. Left ventricular ejection fraction (LVEF) is an 
independent risk factor for mortality regardless of 
patient status at admission measured by the GRACE 
score.
What does this study add?
 ► Adding LVEF to risk evaluation with the GRACE score 
significantly improves accuracy in risk prediction.
How might this impact on clinical practice?
 ► LVEF can be used to improve risk prediction over the 
GRACE score.
 ► Furthermore, LVEF should be systematically record-
ed as well in electronic health records (EHRs) as the 
utilisation of EHR increase in the emerging era of 
‘big data’ in cardiovascular medicine and research.
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over the GRACE score. However, the same study also 
demonstrated that among patients treated by percuta-
neous coronary intervention (PCI), the predictive value 
of GRACE was significantly diminished when compared 
with patients treated conservatively.11
During the past few years, advances have been made 
in the treatment strategies and management of patients 
with acute myocardial infarction (MI).12 For instance, 
the rates of different revascularisation modalities, such as 
coronary artery bypass grafting (CABG) and PCI, have 
increased; this is also the case for primary PCI in the 
management of STEMI. Similarly, LVEF-guided implan-
tation of intracardiac defibrillators (ICD) has been 
introduced in the routine clinical work after the devel-
opment of the GRACE score.13 Furthermore, the use of 
ultrasound in the assessment of LVEF has become main-
stream in clinical work globally after the development of 
GRACE. Ultrasound is also used when assessing the need 
for LVEF-guided implantation of ICDs, a therapy aimed 
to reduce mortality in the long term.
The objectives of this study were to evaluate the predic-
tive value of the GRACE score with respect to 6-month 
mortality and to explore changes in the prognostic perfor-
mance of the GRACE score when adding LVEF data in a 
contemporary setting among consecutive patients treated 
for ACS in a tertiary referral hospital (years 2015 and 
2016). This cohort comprises patients treated according 
to the most recent guidelines with almost exclusive use 
of primary PCI for treatment of ST-elevation infarction, 
predominant use of radial access for angiography, use of 
newer generation drug-eluting stents, use of ticagrelor 
as a first-line adenosine diphosphate (ADP) blocker 
along with all other available emerged medical therapies 
recommended to reduce cardiovascular mortality after 
ACS.5 6 Due to many advances that have transformed the 
treatment of ACS during the last decade, it is important 
to determine whether the risk stratification should be 
updated.
MetHods
study cohort
Mass Data in Detection and Prevention of Serious 
Adverse Events in Cardiovascular Disease (MADDEC) is 
an ongoing, retrospective registry study that integrates 
data from several electronic sources from patients treated 
in a single tertiary care centre, Tays Heart Hospital, which 
is the sole provider of specialised cardiac care for a popu-
lation of approximately 0.5 million inhabitants (hospital 
district of Pirkanmaa, Finland).14
In this study, we investigated patients, who underwent 
coronary angiography for a first episode of ACS during 
a 2-year period (from January 1, 2015 to December 31, 
2016). During this time period, altogether 1795 patients 
underwent coronary angiography for suspected ACS. 
Patients who experienced a type 2 MI, or who were diag-
nosed with some other condition than ACS, were excluded 
from the study population (n=219). Accordingly, 1576 
patients were included in the final analysis. Subjects 
(n=163) who were treated for ACS (unstable angina 
pectoris (UAP) or type I MI) but did not undergo inva-
sive evaluation due to poor medical overall prognosis, 
refusal or for other medical reasons were not included 
in the study. These subjects were on average almost 10 
years older (78 (11) vs 69 (12), p<0.0001) and had higher 
prevalence of dementia (10.5% vs 2.3%, p<0.001), active 
malignancy (6.8% vs 3.4%, p=0.028) and history of cere-
brovascular accident (15.4% vs 8.3%, p=0.002). There 
was no significant difference in sex distribution between 
those undergoing invasive evaluation and those who did 
not (p=0.224).
Due to the nature of this retrospective registry study, 
formal ethical approval was not required. However, the 
present study was approved by the local authority over-
seeing the use of registry data as required by Finnish 
legislature. This study was conducted according to the 
ethical principles of the Declaration of Helsinki on the 
use of human data.
data sources
Clinical cardiovascular phenotype data were collected 
from the KARDIO registry, which includes detailed infor-
mation of patients undergoing invasive operations and 
treated in the coronary care unit and/or at the cardiac 
wards. The study data were collected and added into 
the KARDIO registry by the treating physicians during 
hospitalisation. Additional information, such as patient 
characteristics, laboratory values and length of hospital 
stay, were extracted from the hospital electronic health 
records. Data of prescribed medications at the time of 
discharge, transfer to secondary healthcare provider or 
before death were verified by checking all written patient 
records individually. The data of the main outcome—6-
month mortality—was received from Causes of Death 
register, maintained by Statistic Finland, which records 
100% of deaths of Finnish citizens at home and nearly 
100% abroad.15 16 In this study, the coverage of follow-up 
for mortality was 100% (ie, no loss to follow-up). All 
data collected was integrated into one structured query 
language database hosted in the PostgreSQL version 9.5.
Main outcome and main exposure variables
The main outcome in the present study was 6-month 
all-cause mortality, and the main exposure variables were 
the GRACE score and LVEF. The GRACE score was calcu-
lated for patients based on eight parameters: ST-segment 
deviation, age, heart rate, systolic blood pressure, creati-
nine value, Killip class, cardiac arrest at admission and 
elevated cardiac enzymes (troponin T -levels exceeding 
the 99th upper limit of the population (50 ng/L) on 
admission or within 24 hours of admission). For 35 
patients (2.2%), the calculation was performed after 
imputation of missing values of individual components of 
the GRACE score using multiple imputation by chained 
equations (mice package for R). The echocardiographic 
LVEF was measured for 1556 patients (98.7%) during 
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hospitalisation. Images were obtained from parasternal 
and apical views by treating physicians as a part of routine 
clinical evaluation. LVEF was usually measured from 
multiple views combining information from all areas of 
the left ventricle and the mean value of all measurements 
was combined to form a global estimate of LVEF. After the 
ultrasound, physicians recorded the measurement to the 
KARDIO registry. If the measurement was not recorded 
online, the results of the ultrasound were later retrieved 
from written records and updated to the registry. Impu-
tation was used to estimate the missing 20 values (1.3%).
statistical analysis
Cox regression analysis was used to examine the associ-
ation between the GRACE score and LVEF with predic-
tion of 6-month mortality. The risk associated with the 
GRACE score and LVEF is reported as the hazard ratio 
(HR) related to a one-unit increase in the exposure varia-
bles. Testing of the proportional hazards assumption was 
based on the correlation of survival rankings with Schoen-
feld residuals. All variables fulfilled this assumption. 
Successful model calibration for all models was verified 
with the Hosmer-Lemeshow test. The predictive value of 
different models was estimated by calculating C-statistic 
from the receiving operating characteristics (ROC) 
curves using predicted risk values for 6-month mortality. 
The incremental predictive value of adding LVEF to the 
GRACE score prediction was assessed by the significance 
of the change in C-statistic by the DeLong’s method 
for paired samples (for same subjects of the same study 
population). The incremental predictive value was also 
assessed by the integrated discrimination improvement 
(IDI) depicting the average change in predicted risk 
between individuals with and without the outcome after 
including LVEF into the risk prediction and with contin-
uous net reclassification index (NRI). A p value of 0.05 or 
below was considered statistically significant. All analyses 
were performed using IBM SPSS Statistics (V.21.0) and 
R-software (packages mice, miceadds, PredictABEL and 
pROC).
Results
Baseline demographics and mortality during follow-up
A total of 1576 patients were treated for a first ACS, of 
these 554 (35.2%) had STEMI, 811 (51.5%) NSTEMI, 
while 211 (13.4%) had a final diagnosis of UAP. Demo-
graphic characteristics of the participants are shown in 
table 1. The majority of the patients were male (69.1%), 
and the mean age of the study sample was 69.3 years (SD 
11.9 years). The majority of the patients underwent PCI 
(77.5%, n=1221), while the rates of patients treated by 
CABG (8.1%, n=127) or medical therapy only (14.5%, 
n=228) were substantially lower. Altogether, 106 (6.7%) 
patients died within 6-month follow-up time after ACS. 
A considerable proportion of deaths (n=42, 39.6%) 
occurred among patients with reduced LVEF (<40%). 
Details about the use of antithrombotic medications and 
invasive treatments are presented in the online supple-
ment. Planned pharmacological therapies at discharge or 
at transfer are presented in online supplementary table 1.
Prediction of 6-month mortality
Cox-regression analyses revealed that both the GRACE 
score and LVEF were independently associated with 
6-month mortality. In univariate analysis, the GRACE 
score associated with the risk for mortality with a HR of 
1.040 (95% CIs 1.034 to 1.046, p<0.0001) corresponding 
to a one-unit change in the GRACE score. As expected, 
LVEF was inversely associated with mortality with a 1% 
(unit) change in LVEF corresponding to a HR of 0.927 
(95% CIs 0.911 to 0.942, p<0.0001). The unadjusted 
overall mortality rate across different clinical categories 
of LVEF (reduced: <40%, mildly reduced: 40%–49% and 
normal: ≥50%) are presented in table 2.
After applying both variables into the same model, the 
results remained significant: the GRACE score HR was 
1.036 (95% CIs 1.030 to 1.042, p<0.0001) and the LVEF 
HR 0.965 (95% CIs 0.948 to 0.982, p<0.0001). The changes 
of mortality risk related to LVEF across the continuum 
of LVEF values after adjusting for the GRACE score is 
depicted in figure 1. There was no significant interac-
tion between LVEF and the GRACE score (p=0.397 for 
the interaction), suggesting that the association between 
LVEF and mortality was dependent on patient’s baseline 
risk as evaluated by the GRACE score.
Further adjustments for other comorbidities, such as 
previously suffered major health issues (history of MI, 
stroke, gastrointestinal bleed, anaemia, prior PCI or CABG), 
or prevalent conditions (cancer, valvular heart disease, 
diabetes or chronic obstructive pulmonary disease), did 
not change the adjusted association between LVEF and 
6-month mortality (HR 0.967 with 95% CIs 0.951 to 0.984, 
p=0.0001). Additional adjustment with planned pharmaco-
logical therapies (at discharge, at transfer or before death 
in hospital, factors presented in online supplementary table 
1) or with the type of ACS (UAP, NSTEMI or STEMI) did 
not result in significant change in the association (0.960 
with 95% CIs 0.942 to 0.979, p<0.0001).
Model discrimination was assessed by the C-statistic. 
A model with a C-statistic >0.75 is considered to have 
meaningful discriminatory ability. The GRACE score 
predicted mortality well with a resulting C-statistic value 
of 0.833 (95% CIs 0.795 to 0.871). Applying LVEF in the 
model, the resulting C-statistic was 0.848 (95% CIs 0.813 
to 0.883). The difference in C-statistics was significant 
(p=0.029 for DeLong’s test evaluating difference in C-sta-
tistic for paired samples).
Estimates of continuous reclassification value showed a 
benefit in improving the current model: IDI 0.0171 (95% 
CIs 0.0016 to 0.0327, p=0.031) and NRI of 0.443 (95% CIs 
0.252 to 0.635, p=0.00001).
dIsCussIon
According to the results of the present study, LVEF is an 
independent risk factor for mortality regardless of patient 
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Table 1 Baseline characteristics of patients with ACS evaluated and treated invasively in Tays Heart Hospital in 2015 and 
2016
All
(n=1576)
Dead
(n=106) Survivors (n=1470) P value*
Demographics
  Age (years) 69.26±11.85 76.67±10.17 68.73±11.79 <0.001
  Estimated GFR* 82.1 (26.3) 62.3 (28.4) 83.6 (25.5) <0.001
  Men (%) 1089 (69.1) 58 (54.7) 1031 (70.1) <0.001
  Hypertension, n (%) 963 (61.1) 68 (64.2) 895 (60.9) 0.048
  Dyslipidaemia, n (%) 935 (59.3) 61 (57.5) 874 (59.5) 0.013
  Diabetes, n (%) 389 (24.7) 43 (40.6) 346 (23.5) <0.001
  Previous MI, n (%) 309 (19.6) 35 (33.0) 274 (18.6) <0.001
  Peripheral artery disease, n (%) 119 (7.6) 20 (18.9) 99 (6.7) <0.001
  Previous PCI, n (%) 320 (17.8) 21 (19.8) 261 (17.8) 0.594
  Previous CABG, n (%) 165 (6.5) 16 (15.1) 122 (8.3) 0.017
On admission data
  Type of ACS, n (%) <0.001
   UAP 211 (13.4) 4 (3.8) 207 (14.1)
   NSTEMI 811 (51.5) 49 (46.2) 762 (51.8)
   STEMI 554 (35.2) 53 (50.0) 501 (34.1)
  Killip class, n (%) <0.001
  I 1267 (80.4) 45 (42.5) 1222 (83.1)
  II 190 (12.1) 21 (19.8) 169 (11.5)
  III 93 (5.9) 22 (20.8) 71 (4.8)
  IV 26 (1.6) 18 (17.0) 8 (0.5)
Heart rate (beats per min) 79.11±20.53 86.02±22.71 78.63±20.29 <0.001
Systolic blood pressure (mm Hg) 144.11±29.04 128.27±31.84 145.22±28.51 <0.001
Serum creatinine level (µmol/L) 90.91±58.67 120.40±71.37 88.79±57.08 <0.001
Cardiac arrest at admission, n (%) 89 (5.6) 21 (19.8) 68 (4.6) <0.001
TnT elevated (>50 ng/L)‡, n (%) 1335 (84.7) 103 (97.2) 1232 (83.8) <0.001
ST-segment shift§, n (%) 1036 (65.7) 90 (84.9) 946 (64.4) <0.001
GRACE score 119.92±33.67 163.36±35.69 116.79±31.29 <0.001
Ejection fraction 50.61±11.004 41.21±11.92 51.29±10.62 <0.001
Categorical variables are expressed in frequency and percentage and continuous variables are presented as mean±SD.
*For comparison between patients who were dead at 6 months and survivors.
†Estimated glomerular filtration rate (mL/min/1.73 m2).
‡Exceeding the 99th percentile for general population.
§Significant ST-elevation or ST-segment depression in two consecutive leads.
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting;GFR, glomerular filtration rate; GRACE, Global Registry of Acute 
Coronary Events; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction;PCI, percutaneous coronary intervention; STEMI, 
ST-elevation myocardial infarction; TnT, troponin t; UAP, unstable angina pectoris.
status at admission measured by the GRACE score. 
Adding LVEF to risk prediction with the GRACE score 
resulted in significant improvement in risk stratification.
To the best of our knowledge, there is only one previous 
study published on the possible incremental predictive 
value of adding LVEF to risk prediction beyond the 
GRACE score in patients with ACS.11 The retrospec-
tive MASCARA registry study by Abu-Assi et al11 of 3.960 
patients treated in 2004–2005 found no incremental 
benefit of adding LVEF to the GRACE score in predicting 
6-month mortality postdischarge or in-hospital mortality 
among patients with MI. The different study results might, 
at least partly, be explained by the many advances that 
have transformed the medical and invasive treatment of 
ACS during the last decade. In the MASCARA registry,11 
the revascularisation rate by any method was only 18%, 
which is in stark contrast with the corresponding figure 
of 86% in the present study. Furthermore, rather than 
using LVEF as a continuous variable as in the present 
study, LVEF was categorised in three risk categories in the 
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Table 2 The unadjusted overall mortality rate and status on admission across different clinical categories of left ventricular 
ejection fraction (LVEF) (reduced <40%, mildly reduced 40%–49% and normal ≥50%)
LVEF <40% (n=210) LVEF 40%–49% (n=357) LVEF >50% (n=1009) P value
Dead at 6 months, n (%) 42 (20.0) 31 (8.7) 33 (3.3) <0.001
Age 71.50±12.06 70.23±11.95 68.45±11.70 <0.001
Men, n (%) 147 (70.0) 250 (70.0) 692 (68.6) 0.839
GRACE score 144.11±34.12 128.55±30.88 111.83±31.30 <0.001
Type of ACS, n (%)       <0.001
  UAP 6 (2.9) 29 (8.1) 176 (17.4)
  NSTEMI 99 (47.1) 156 (43.7) 556 (55.1)
  STEMI 105 (50.5) 172 (48.2) 277 (27.5)
Killip class, n (%)       <0.001
  I 92 (43.8) 261 (73.1) 914 (90.6)
  II 62 (29.5) 61 (17.1) 67 (6.6)
  III 41 (19.5) 30 (8.4) 22 (2.2)
  IV 15 (7.1) 5 (1.4) 6 (0.6)
ACS, acute coronary syndrome;GRACE, Global Registry of Acute Coronary Events; NSTEMI, non-ST-elevation myocardial infarction; STEMI, 
ST-elevation myocardial infarction; UAP, unstable angina pectoris.
Figure 1 The association between left ventricular ejection 
fraction and 6-month mortality after adjusting for patients’ 
baseline risk as evaluated by grace score depicting patients’ 
status on admission for acute coronary syndrome.
MASCARA registry; this could result in diminished statis-
tical power for detecting independent associations and 
incremental value of adding LVEF to the risk prediction. 
Supporting our findings, previous studies have shown that 
LVEF is an independent risk marker for mortality after 
ACS, even after accounting for other clinical risk factors 
related to comorbidities and status on admission. This 
was the case even after including Killip classification for 
heart failure, ST-segment abnormalities, cardiac enzyme 
levels and haemodynamic status, which are included in 
the GRACE score.8 9 17 18
Despite the fact that the GRACE score was intro-
duced almost two decades ago, it still represents the 
best possible validated method for estimating the risk 
of mortality after ACS,3 and its use is recommended 
by current guidelines.5–7 After the onset of the new era 
of ‘big data’, the discovery of novel risk factors, which 
can add to risk prediction over clinically relevant risk 
markers, is important.19 Systematic recording of risk 
factors, such as LVEF, should be applied universally as 
the utilisation of registry information used to model 
patient survival becomes the norm.19
The limitation of the present study is that the GRACE 
score information was collected retrospectively and 
therefore was not available for all subjects. However, 
data were missing only for approximately 2.6% of the 
subjects. Retrospective collection can also be less accu-
rate in capturing relevant information when compared 
with a dedicated online data collection protocol. 
Despite of these shortcomings, the GRACE score 
recorded in our study performed very well, with the 
C-statistic (0.83) very close to the value expected for 
prediction of 6-month mortality based on meta-anal-
ysis of all previous observational studies (meta-anal-
ysed C-statistic of 0.84).3 The foremost strength of the 
present study is that it includes all consecutive patients 
diagnosed and treated invasively for ACS during the 
time of the study. Furthermore, due to the centralised 
nature of Finnish national registries, there was no loss 
of mortality data for follow-up.
In conclusion, the GRACE score remains a good 
predictor of all-cause mortality in a contemporary setting. 
However, LVEF is an independent risk marker for death 
after ACS despite patient’s comorbidities and status as 
measured by the GRACE score. LVEF can be used to 
improve risk prediction over the GRACE score.
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